capmatinib
Selected indexed studies
- Capmatinib. (, 2012) [PMID:37782740]
- Capmatinib. (, 2006) [PMID:37247365]
- Capmatinib: First Approval. (Drugs, 2020) [PMID:32557339]
_Worker-drafted node — pending editorial review._
Connections
capmatinib is a side effect of
Sources
- Capmatinib. (2012) pubmed
- Capmatinib. (2006) pubmed
- Capmatinib: First Approval. (2020) pubmed
- Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. (2020) pubmed
- Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. (2024) pubmed
- Capmatinib for non-small cell lung cancer. (2021) pubmed
- Capmatinib for the treatment of non-small cell lung cancer. (2019) pubmed
- Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study. (2024) pubmed
- Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy. (2024) pubmed
- Capmatinib suppresses LPS-induced interaction between HUVECs and THP-1 monocytes through suppression of inflammatory responses. (2023) pubmed